Exon 20 Insertion Mutant EGFR-Based Detection and Monitoring Systems

Publication ID: 24-11857513_0007_PTD
Published: October 28, 2025
Category:New Applications & Use Cases

Legal Citation

pr1or.art Inc., “Exon 20 Insertion Mutant EGFR-Based Detection and Monitoring Systems,” Published Technical Disclosure No. 24-11857513_0007_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857513_0007_PTD
This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,513.

Summary of the Inventive Concept

The inventive concept applies the core technology of selective inhibitors of exon 20 insertion mutant EGFR to develop innovative detection and monitoring systems for various industries, including wildfire detection, water quality monitoring, invasive species tracking, agricultural pest control, and neurological disorder diagnosis.

Background and Problem Solved

The original patent focused on antitumor agents for treating cancers with EGFR having exon 20 insertion mutations. However, the detection and monitoring of such mutations have broader applications beyond cancer treatment. The new inventive concept addresses the need for efficient and accurate detection methods in various fields, leveraging the core technology of the original patent.

Detailed Description of the Inventive Concept

The inventive concept encompasses a range of systems and methods that utilize exon 20 insertion mutant EGFR-based detection methods. For instance, a wildfire detection system can employ sensors to detect EGFR having exon 20 insertion mutations in environmental samples, triggering alerts to firefighters. Similarly, a water quality monitoring system can detect EGFR mutations in water samples to generate reports on water quality. The inventive concept also extends to invasive species tracking, agricultural pest control, and neurological disorder diagnosis, where the detection of EGFR mutations enables targeted interventions and treatments.

Novelty and Inventive Step

The new claims introduce novel applications of exon 20 insertion mutant EGFR-based detection methods, moving beyond cancer treatment to address pressing issues in various industries. The inventive step lies in the recognition of the broader potential of this technology and its adaptation to new fields, resulting in innovative solutions that were not obvious from the original patent.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the development of portable detection devices, integration with existing monitoring systems, or the use of machine learning algorithms to enhance detection accuracy. Variations of the inventive concept could also explore the application of exon 20 insertion mutant EGFR-based detection methods to other fields, such as environmental monitoring or forensic analysis.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential across multiple industries, including environmental monitoring, agriculture, and healthcare. The market for such detection and monitoring systems is substantial, driven by the need for efficient and accurate solutions to pressing problems in these fields. The inventive concept offers a unique value proposition, enabling the development of innovative products and services that can address these needs and create new business opportunities.

CPC Classifications

SectionClassGroup
A A61 A61K31/519
A A61 A61P35/00

Original Patent Information

Patent NumberUS 11,857,513
TitleSelective inhibitor of exon 20 insertion mutant EGFR
Assignee(s)TAIHO PHARMACEUTICAL CO., LTD.